YORBA LINDA, Calif. (PRWEB) November 22, 2017
The benefits of genomic analysis are well understood, however, the majority of patients do not harbor druggable alterations in their genomes and thus are not candidates for targeted therapies. In patients whose tumors lack genomic biomarkers for targeted therapies or have developed resistance, clinical proteomics is identifying protein biomarkers for therapies that are benefitting patients, and fueling the emergence of proteogenomics.
This webinar will cover the assay development pipeline utilized to bring these quantitative proteomic markers into our CAP-CLIA laboratory. Starting from a targeted-discovery initiative to the analytical validation of our multiplexed SRM methods, an overview and discussion will cover the metrics used to validate assays.
Additionally, this webinar will introduce the impact these developed markers have on clinical research, including the retrospective analyses of HER2 proteomic expression in adjuvant and metastatic breast cancer and in advanced gastric cancer. Participants will better understand the metrics used to analytically validate a multiplexed proteomic LC-MS assay. They will also learn of the workflows and processes used in working with Liquid Tissue®.
For Research Use Only. Not for use in diagnostic procedures.
Dr. Todd Hembrough, President of Proteomics of NantOmics and Dr. Maryann Vogelsang, the manager of Assay Development with NantOmics, will be the speakers for this event.
Hembrough obtained his doctorate in biochemistry from the University of Virginia, studying the role of proteinases in tumor growth and invasion. Prior to NantOmics, he was a leader of the translational oncology efforts at EntreMed, focusing on defining druggable molecular pathways and inventing new drugs to target these pathways.
Vogelsang earned her doctorate in biochemistry and molecular biology from the University of California, Los Angeles. Prior to NantOmics, she established a CLIA compliant laboratory that offered both ELISA- and MS-based clinical assays. She has more than a decade of experience in translational medicine utilizing the mass spectrometry platform.
LabRoots will host the event, sponsored by Thermo Fisher Scientific, on December 14, 2017, beginning at 8:00 a.m. PST, 5:00 p.m. CEST. To learn more about the webinar, discover the continuing education credits offered, or to register for free, click here.
LabRoots is the leading scientific social networking website, which provides daily scientific trending news, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.